Holen Sie sich die Stockscreener-App
90.24
1.01%
0.90
Handel nachbörslich:
90.29
0.05
+0.06%
Schlusskurs vom Vortag:
$89.34
Offen:
$90.56
24-Stunden-Volumen:
343.81K
Relative Volume:
0.36
Marktkapitalisierung:
$4.91B
Einnahmen:
$2.04M
Nettoeinkommen (Verlust:
$-162.34M
KGV:
-21.94
EPS:
-4.1129
Netto-Cashflow:
$-129.27M
1W Leistung:
+7.85%
1M Leistung:
+4.93%
6M Leistung:
+167.54%
1J Leistung:
+318.75%
1-Tages-Spanne:
$87.93
$90.90
1-Wochen-Bereich:
$82.00
$91.04
52-Wochen-Spanne:
$16.64
$96.50
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Firmenname
Dianthus Therapeutics Inc
Sektor
Branche
Telefon
929-999-4055
Adresse
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
90.24 | 4.86B | 2.04M | -162.34M | -129.27M | -4.1129 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-10-14 | Eingeleitet | Truist | Buy |
| 2025-07-02 | Eingeleitet | William Blair | Outperform |
| 2024-12-20 | Eingeleitet | TD Cowen | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-15 | Eingeleitet | Stifel | Buy |
| 2023-12-26 | Eingeleitet | Jefferies | Buy |
| 2023-11-22 | Eingeleitet | Wedbush | Outperform |
| 2023-10-30 | Eingeleitet | Guggenheim | Buy |
| 2023-09-28 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-06 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-20 | Fortgesetzt | Goldman | Neutral |
| 2021-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Bestätigt | B. Riley Securities | Buy |
| 2021-06-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-18 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-07 | Eingeleitet | Mizuho | Buy |
| 2020-06-08 | Hochstufung | Goldman | Neutral → Buy |
| 2019-03-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis - GlobeNewswire Inc.
Dianthus Therapeutics (NASDAQ:DNTH) Releases Earnings Results, Beats Expectations By $0.25 EPS - MarketBeat
Dianthus Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Earnings Flash (DNTH) Dianthus Therapeutics, Inc. Reports Q1 Revenue $463K, vs. FactSet Est of $404K - marketscreener.com
Dianthus Therapeutics (NASDAQ: DNTH) builds $1.1B cash to fund autoimmune pipeline - Stock Titan
Dianthus got 20 responders before 40 patients in CIDP trial - Stock Titan
Dianthus (Nasdaq: DNTH) raises $719M, ends Q1 2026 with $1.2B cash - Stock Titan
Dianthus Therapeutics (DNTH) to Release Earnings on Monday - MarketBeat
MSN Money - MSN
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Six new Dianthus hires get options to buy 135,000 shares - Stock Titan
Dianthus Therapeutics (DNTH) price target increased by 70.00% to 130.48 - MSN
Short Interest in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Decreases By 27.6% - MarketBeat
Assessing Dianthus Therapeutics (DNTH) Valuation After FDA Trial Shift And Renewed Analyst Optimism - Yahoo Finance
BlackRock holds 2.63M Dianthus shares (NASDAQ: DNTH) — 5.1% stake - Stock Titan
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
Does Dianthus Therapeutics (DNTH) Trial Easing Quietly Redefine Its Long-Term Neuromuscular Strategy? - Sahm
Certain Stock Options of Dianthus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2026. - marketscreener.com
Dianthus Therapeutics announces proposed $400 million public share offering - MSN
Dianthus rises as FDA agrees with proposed changes to lead program - MSN
Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier - Insider Monkey
5 Best 52-Week High US Stocks to Buy - Insider Monkey
Dianthus (DNTH) Investment Thesis | Dianthus Therapeutics Inc posts 30.3% EPS miss with no revenueHedge Fund Inspired Picks - Cổng thông tin điện tử Tỉnh Sơn La
Dianthus Therapeutics CFO Sells All Shares in 2026 Transaction | Company UpdateNews and Statistics - IndexBox
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000 - AOL.com
Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target - MSN
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: Exploring a 35% Upside Potential Amid Biotech Innovations - DirectorsTalk Interviews
Dianthus Therapeutics (DNTH) Is Up 10.1% After $719M Raise And Insider Sale Has The Bull Case Changed? - Sahm
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Dianthus Therapeutics CFO Sells $9.5 Million in Stock - AOL.com
Dianthus Therapeutics shares jump 25% after encouraging clinical trial update - MSN
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year HighShould You Buy? - MarketBeat
Dianthus Therapeutics EVP Sells $10M in Shares - National Today
SG Americas Securities LLC Invests $765,000 in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
DNTH SEC FilingsDianthus Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Dianthus Therapeutics (NASDAQ:DNTH) EVP Ryan Savitz Sells 8,224 Shares - MarketBeat
Ryan Savitz, Dianthus Therapeutics CFO, sells $738k in DNTH stock - Investing.com Canada
Dianthus Therapeutics Insider Sold Shares Worth $738,844, According to a Recent SEC Filing - marketscreener.com
Dianthus (NASDAQ: DNTH) CFO exercises options, sells 8,224 shares under 10b5-1 plan - Stock Titan
Dianthus Therapeutics Upgraded to Strong Buy at Wolfe Research - National Today
Dianthus Therapeutics (NASDAQ:DNTH) Upgraded by Wolfe Research to "Strong-Buy" Rating - MarketBeat
Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):